why choose us

First received: September 20, 2023

Clinical Trial: A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Relapsed or Refractory Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Randomized Phase IB/II Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple

Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in participants with relapsed or refractory multiple myeloma (r/r MM).The study consists of two phases: a dose exploration phase and a dose-expansion phase.

Read more